Toxic neuropathy after adenine arabinoside treatment in chronic HBsAg-positive liver disease

J Clin Gastroenterol. 1990 Feb;12(1):90-2. doi: 10.1097/00004836-199002000-00023.

Abstract

A 62-year-old woman with hepatitis-B-surface-antigen-positive hepatic cirrhosis presented with weakness and paresthesias over the distal part of the limbs in the course of adenine arabinoside 5'-monophosphate (ARA-AMP) treatment, and recovered spontaneously after several weeks of drug withdrawal. Electrophysiological and histological studies demonstrated axonal neuropathy. Although the patient received a relatively low total dose (120 mg/kg), her age and advanced liver disease may have played a role in the ARA-AMP neurotoxicity.

Publication types

  • Case Reports

MeSH terms

  • Arabinonucleotides / adverse effects*
  • Chronic Disease
  • Female
  • Hepatitis B Surface Antigens / analysis
  • Humans
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / microbiology
  • Middle Aged
  • Paresthesia / chemically induced
  • Peripheral Nervous System Diseases / chemically induced*
  • Vidarabine Phosphate / adverse effects*
  • Vidarabine Phosphate / therapeutic use

Substances

  • Arabinonucleotides
  • Hepatitis B Surface Antigens
  • Vidarabine Phosphate